Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Different Drugs to Control Post Root Canal Treatment Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient reported spontaneous pain moderate to severe, ranging from 50 to 100 mm on a VAS (0-100 mm);~2. Adult patients presented for emergency endodontic treatment with a symptomatic maxillary or mandibular tooth (anterior and premolar) with a pulpal diagnosis of Irreversible pulpitis and normal periapex.~3. Patient choose to have root canal treatment for pain of endodontic origin.~4. The patient presented with American Society of Anesthesiologists (ASA) I or II medical history (ASA 1963).~5. The patient had read and thoroughly understood the pain score level sheet~Exclusion Criteria:~1. Patients below 18 years of age;~2. Analgesic taken within the last 4 hours;~3. History of allergy to NSAIDs, paracetamol or local anaesthetics;~4. History of uncontrolled systemic disease \[gastrointestinal (GI) disorders, oesophageal reflux, active asthma, decreased hepatic function, haemorrhagic disorders, or poorly controlled diabetes mellitus\].~5. Patients currently taking opioids, monoamine oxidase inhibitors, tricyclic antidepresssants, carbamazepine, diuretics, or anticoagulants;~6. There was history of opioid addiction or abuse; and~7. Pregnant or nursing female patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Group I (Type: ACTIVE_COMPARATOR): paracetamol 1000mg
- Group II (Type: EXPERIMENTAL): ibuprofen 600mg + paracetamol 1000mg,
- Group III (Type: EXPERIMENTAL): Mefenamic acid 500mg + Paracetamol 1000mg
- Group IV (Type: EXPERIMENTAL): Diclofenac K 50mg + paracetamol 1000 mg
- Group V (Type: PLACEBO_COMPARATOR): No medication

Based on this trial design, predict the completion outcome and termination type (if applicable).